Gemcitabine Inhibits the Progression of Pancreatic Cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Pancreatic cancer (PC) is a common malignant tumor of the digestive system, and its 5-year survival rate is only 4%. N6-methyladenosine (m6A) RNA methylation is the most common post-transcriptional modification and dynamically regulates cancer development, while its role in PC treatment remains unclear.Materials and Methods We treated PC cells with gemcitabine and quantified the overall m6A level with m6A methylation quantification. Real-time quantitative reverse transcription polymerase chain reaction and Western blot analyses were used to detect expression changes of m6A regulators. We verified the m6A modification on the target genes through m6A-immunoprecipitation (IP), and further <i>in vivo</i> experiments and immunofluorescence (IF) assays were applied to verify regulation of gemcitabine on Wilms’ tumor 1–associated protein (WTAP) and MYC.Results Gemcitabine inhibited the proliferation and migration of PC cells and reduced the overall level of m6A modification. Additionally, the expression of the “writer” WTAP was significantly downregulated after gemcitabine treatment. We knocked down WTAP in cells and found target gene MYC expression was significantly downregulated, m6A-IP also confirmed the m6A modification on MYC. Our experiments showed that m6A-MYC may be recognized by the “reader” IGF2BP1. <i>In vivo</i> experiments revealed gemcitabine inhibited the tumorigenic ability of PC cells. IF analysis also showed that gemcitabine inhibited the expression of WTAP and MYC, which displayed a significant trend of co-expression.Conclusion Our study confirmed that gemcitabine interferes with WTAP protein expression in PC, reduces m6A modification on MYC and RNA stability, thereby inhibiting the downstream pathway of MYC, and inhibits the progression of PC.
Abstract
Purpose Pancreatic cancer (PC) is a common malignant tumor of the digestive system, and its 5-year survival rate is only 4%. N6-methyladenosine (m6A) RNA methylation is the most common post-transcriptional modification and dynamically regulates cancer development, while its role in PC treatment remains unclear.Materials and Methods We treated PC cells with gemcitabine and quantified the overall m6A level with m6A methylation quantification. Real-time quantitative reverse transcription polymerase chain reaction and Western blot analyses were used to detect expression changes of m6A regulators. We verified the m6A modification on the target genes through m6A-immunoprecipitation (IP), and further <i>in vivo</i> experiments and immunofluorescence (IF) assays were applied to verify regulation of gemcitabine on Wilms’ tumor 1–associated protein (WTAP) and MYC.Results Gemcitabine inhibited the proliferation and migration of PC cells and reduced the overall level of m6A modification. Additionally, the expression of the “writer” WTAP was significantly downregulated after gemcitabine treatment. We knocked down WTAP in cells and found target gene MYC expression was significantly downregulated, m6A-IP also confirmed the m6A modification on MYC. Our experiments showed that m6A-MYC may be recognized by the “reader” IGF2BP1. <i>In vivo</i> experiments revealed gemcitabine inhibited the tumorigenic ability of PC cells. IF analysis also showed that gemcitabine inhibited the expression of WTAP and MYC, which displayed a significant trend of co-expression.Conclusion Our study confirmed that gemcitabine interferes with WTAP protein expression in PC, reduces m6A modification on MYC and RNA stability, thereby inhibiting the downstream pathway of MYC, and inhibits the progression of PC.
참고문헌 (30)
- Siegel RL, "Cancer statistics, 2019", CA Can cer J Clin, 69, pp.7~34 (2019)
- Neoptolemos JP, "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer", N Engl J Med, 350, pp.1200~1210 (2004)
- Siegel RL, "Cancer statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
- Roundtree IA, "Dynamic RNA modifi cations in gene expression regulation", Cell, 169, pp.1187~1200 (2017)
- Zhao BS, "Post-transcriptional gene regu lation by mRNA modifications", Nat Rev Mol Cell Biol, 18, pp.31~42 (2017)
- Guo X, "RNA dem ethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2dependent manner", Mol Cancer, 19, pp.91~ (2020)
- Hu X, "IGF2BP2 regulates DANCR by serving as an N6-methyladen osine reader", Cell Death Differ, 27, pp.1782~1794 (2020)
- Wang M, "Upregula tion of METTL14 mediates the elevation of PERP mRNA N6adenosine methylation promoting the growth and metastasis of pancreatic cancer", Mol Cancer, 19, pp.130~ (2020)
- Taketo K, "The epitranscriptome m6A writer METTL3 promotes chemo-and radioresistance in pancreatic cancer cells", Int J Oncol, 52, pp.621~629 (2018)
- Hertel LW, "Evaluation of the antitumor activity of gemcitabine(2’, 2’-difluoro-2’-deoxycytidine)", Cancer Res, 50, pp.4417~4422 (1990)
- Xu BQ, "Gemcitabine enhances cell invasion via activating HAb18G", CD147-EGFR pSTAT3 signaling, 2016, pp.7, 62177~62193
- Gao P, "c-Myc suppression of miR-23a", b enhances mitochondrial glutaminase expression and glutamine metabolism, 2009, pp.458, 762~765
- Dong P, "Division of labour between Myc and G1 cyc lins in cell cycle commitment and pace control", Nat Commun, 5, pp.4750~ (2014)
- Zhu S, "An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis", Nat Commun, 11, pp.1685~ (2020)
- Zhu P, "A novel hypoxic long noncoding RNA KB-1980E6. 3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability", Oncogene, 40, pp.1609~1627 (2021)
- Kleeff J, "Surgery for recurrent pancreatic ductal adenocarcinoma", Ann Surg, 245, pp.566~572 (2007)
- Raimondi S, "Epidemiology of pancreatic cancer : an overview", Nat Rev Gastroenterol Hepa tol, 6, pp.699~708 (2009)
- Omura N, "Epigenetics and epigenetic alterations in pancreatic cancer", Int J Clin Exp Pathol, 2, pp.310~326 (2009)
- Huxley R, "Type-II diabetes and pancreatic cancer : a meta-analysis of 36 studies", Br J Cancer, 92, pp.2076~2083 (2005)
- Duell EJ, "Pancreatitis and pancreatic cancer risk : a pooled analysis in the International Pancreatic Cancer Case-Control Consortium(PanC4)", Ann Oncol, 23, pp.2964~2970 (2012)
- Ligorio M, "Stromal microenvironment shapes the intratu moral architecture of pancreatic cancer", Cell, 178, pp.160~175 (2019)
- Zhu H, "Pancreatic cancer : challenges and opportunities", BMC Med, 16, pp.214~ (2018)
- Barbieri I, "Role of RNA modifications in cancer", Nat Rev Cancer, 20, pp.303~322 (2020)
- Zhou Z, "Mechanism of RNA modification N6-methyladenosine in human cancer", Mol Cancer, 19, pp.104~ (2020)
- Han J, "METTL3promote tumor proliferation of bladder cancer by accelerating pri-miR221", 222 maturation in m6A-dependent manner, 2019, pp.18, 110~
- Yang X, "METTL14suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST", Mol Cancer, 19, pp.46~ (2020)
- Liu T, "The m6A reader YTHDF1 promotes ovarian cancer progression via augment ing EIF3C translation", Nucleic Acids Res, 48, pp.3816~3831 (2020)
- Heinemann V, "Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer", J Clin Oncol, 24, pp.3946~3952 (2006)
- Dang CV, "The c-Myc target gene network", Semin Cancer Biol, 16, pp.253~264 (2006)
- Meyer N, "Reflecting on 25 years with MYC", Nat Rev Cancer, 8, pp.976~990 (2008)